Postmenopausal Osteoporosis and Osteopenia Management with a Combination of Once-Monthly Oral Ibandronate and Cholecalciferol—A Systematic Review — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Postmenopausal Osteoporosis and Osteopenia Management with a Combination of Once-Monthly Oral Ibandronate and Cholecalciferol—A Systematic Review
Teresópolis Medical Faculty, Rio de Janeiro Federal University, Rua Bruno Lobo, Brazil
,
Carlos Chagas Post-graduation Institute, Rio de Janeiro, Brazil
,
Orthopedic Surgery and Trauma National Institute, Rio de Janeiro, Brazil
,
Weill Medical College of Cornell University, New York, USA
,
Lenox Hill Hospital Northwell Health, New York, USA
,
Fluminense Federal University, Antonio Pedro Hospital, Rio de Janeiro, Brazil
,
New Jersey Medical School, New York, USA
1 Teresópolis Medical Faculty, Rio de Janeiro Federal University, Rua Bruno Lobo, Brazil
2 Carlos Chagas Post-graduation Institute, Rio de Janeiro, Brazil
3 Orthopedic Surgery and Trauma National Institute, Rio de Janeiro, Brazil
4 Weill Medical College of Cornell University, New York, USA
5 Lenox Hill Hospital Northwell Health, New York, USA
6 Fluminense Federal University, Antonio Pedro Hospital, Rio de Janeiro, Brazil
Postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.
Frampton, J.E. and Perry, C.M. (2008) Ibandronate: A Review of Its Use in the Management of Postmenopausal Osteoporosis. Drugs, 68, 2683-2707. https://doi.org/10.2165/0003495-200868180-00011
Hasan, W.N.W., Chin, K.Y., Jolly, J.J., et al. (2018) Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism. Endocrine, Metabolic and Immune Disorders—Drug Targets, 18, 450-457. https://doi.org/10.2174/1871530318666180423122409
LeBoff, M.S., Greenspan, S.L., Insogna, K.L., et al. (2022) The Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 33, 2049-2102. https://doi.org/10.1007/s00198-021-05900-y
Maraka, S. and Kennel, K.A. (2015) Bisphosphonates for the Prevention and Treatment of Osteoporosis. BMJ, 351, h3783. https://doi.org/10.1136/bmj.h3783
Selçuk, A.A. (2019) A Guide for Systematic Reviews: PRISMA. Turkish Archives of Otorhinolaryngology, 57, 57-58. https://doi.org/10.5152/tao.2019.4058
Chesnut III, C.H. (2006) Treating Osteoporosis with Bisphosphonates and Addressing Adherence: A Review of Oral Ibandronate. Drugs, 66, 1351-1359. https://doi.org/10.2165/00003495-200666100-00004
Ali, N., Jurczyluk, J., Shay, G., et al. (2015) A Highly Sensitive Prenylation Assay Reveals in Vivo Effects of Bisphosphonate Drug on the Rab Prenylome of Macrophages outside the Skeleton. Small GTPases, 6, 202-211. https://doi.org/10.1080/21541248.2015.1085485
drugbank.com (2022) Vitamin D3: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB00169
Vieth, R. (2020) Vitamin D Supplementation: Cholecalciferol, Calcifediol, and Calcitriol. The European Journal of Clinical Nutrition, 74, 1493-1497. https://doi.org/10.1038/s41430-020-0697-1
Holick, M.F. (2017) The Vitamin D Deficiency Pandemic: Approaches for Diagnosis, Treatment and Prevention. Reviews in Endocrine and Metabolic Disorders, 18, 153-165. https://doi.org/10.1007/s11154-017-9424-1
Jeon, J.-Y., Lee, S.Y., Im, Y.-J., et al. (2014) Comparison of the Pharmacokinetics, Safety, and Tolerability of Vitamin D3 in DP-R206 (150-mg Ibandronate/24,000-IU Vitamin D3 Tablet) and as Monotherapy (24,000 IU) in Healthy Male Korean Adults. Clinical Therapeutics, 36, 48-57. https://doi.org/10.1016/j.clinthera.2013.12.001
Cho, I.J., Chung, H.Y., Kim, S.W., et al. (2015) Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. Endocrinology and Metabolism (Seoul), 30, 272-279. https://doi.org/10.3803/EnM.2015.30.3.272
Yoon, S.H. (2017) A Monthly Combined Agent of Ibandronate and Cholecalciferol Is Effective in Bone Metabolism but Not in Muscle Strength and Bone Mineral Density in Korean Postmenopausal Women with Osteoporosis. Maturitas, 100, 158. https://doi.org/10.1016/j.maturitas.2017.03.142
Binkley, N., Silverman, S.L., Simonelli, C., et al. (2009) Monthly Ibandronate Suppresses Serum CTX-I within 3 Days and Maintains a Monthly Fluctuating Pattern of Suppression. Osteoporosis International, 20, 1595-1601. https://doi.org/10.1007/s00198-008-0827-4
Binkley, N., Martens, M.G., Silverman, S.L., et al. (2009) Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates. Southern Medical Journal, 102, 486-492. https://doi.org/10.1097/SMJ.0b013e31819ed0dd
Bock, O., Börst, H., Beller, G., et al. (2012) Impact of Oral Ibandronate 150 mg Once Monthly on Bone Structure and Density in Postmenopausal Osteoporosis or Osteopenia Derived from in Vivo μCT. Bone, 50, 317-324. https://doi.org/10.1016/j.bone.2011.10.027
Bonnick, S.L., Silverman, S., Tanner, S.B., et al. (2009) Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate. Journal of Women’s Health (Larchmt), 18, 935-943. https://doi.org/10.1089/jwh.2008.1064
Chapurlat, R.D., Laroche, M., Thomas, T., et al. (2013) Effect of Oral Monthly Ibandronate on Bone Microarchitecture in Women with Osteopenia—A Randomized Placebo-Controlled Trial. Osteoporosis International, 24, 311-320. https://doi.org/10.1007/s00198-012-1947-4
Emkey, R., Koltun, W., Beusterien, K., et al. (2005) Patient Preference for Once-Monthly Ibandronate versus Once-Weekly Alendronate in a Randomized, Open-Label, Cross-Over Trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Current Medical Research and Opinion, 21, 1895-1903. https://doi.org/10.1185/030079905X74862
Emkey, R., Delmas, P.D., Bolognese, M., et al. (2009) Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results from the Monthly Oral Therapy with Ibandronate for Osteoporosis Intervention (MOTION) Study. Clinical Therapeutics, 31, 751-761. https://doi.org/10.1016/j.clinthera.2009.04.018
Engelke, K., Fuerst, T., Enslin, M.B., et al. (2009) Regional Differences of Spinal BMD Changes after One Year Once-Monthly Ibandronate as Measured by 3D QCT. Journal of Clinical Densitometry, 12, 120. https://doi.org/10.1016/j.jocd.2008.07.076
Engelke, K., Fuerst, T., Dasic, G., et al. (2010) Regional Distribution of Spine and Hip QCT BMD Responses after One Year of Once-Monthly Ibandronate in Postmenopausal Osteoporosis. Bone, 46, 1626-1632. https://doi.org/10.1016/j.bone.2010.03.003
Lewiecki, E.M., Keaveny, T.M., Kopperdahl, D.L., et al. (2009) Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 94, 171-180. https://doi.org/10.1210/jc.2008-1807
McClung, M.R., Bolognese, M.A., Sedarati, F., et al. (2009) Efficacy and Safety of Monthly Oral Ibandronate in the Prevention of Postmenopausal Bone Loss. Bone, 44, 418-422. https://doi.org/10.1016/j.bone.2008.09.011
Miller, P.D., McClung, M.R., Macovei, L., et al. (2005) Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results from the MOBILE Study. Journal of Bone and Mineral Research, 20, 1315-1322. https://doi.org/10.1359/JBMR.050313
Miller, P.D., Epstein, S., Sedarati, F., et al. (2008) Once-Monthly Oral Ibandronate Compared with Weekly Oral Alendronate in Postmenopausal Osteoporosis: Results from the Head-to-Head MOTION Study. Current Medical Research and Opinion, 24, 207-213. https://doi.org/10.1185/030079908X253889
Miller, P.D., Recker, R.R., Reginster, J.-Y., et al. (2012) Efficacy of Monthly Oral Ibandronate Is Sustained over 5 Years: The MOBILE Long-Term Extension Study. Osteoporosis International, 23, 1747-1756. https://doi.org/10.1007/s00198-011-1773-0
Nakamura, T., Mizunuma, H., Itabashi, A., et al. (2007) Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Japanese Osteoporotic Subjects. Journal of Bone and Mineral Research, 22, S333.
Reginster, J.-Y., Adami, S., Lakatos, P., et al. (2006) Efficacy and Tolerability of Once-Monthly Oral Ibandronate in Postmenopausal Osteoporosis: 2 Year Results from the MOBILE Study. Annals of Rheumatic Diseases, 65, 654-661. https://doi.org/10.1136/ard.2005.044958
Stakkestad, J.A., Lakatos, P., Lorenc, R., et al. (2008) Monthly Oral Ibandronate Is Effective and Well Tolerated after 3 Years: The MOBILE Long-Term Extension. Clinical Rheumatology, 27, 955-960. https://doi.org/10.1007/s10067-007-0824-6